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ABSTRACT
Introduction: Chronic low back pain (LBP)
caused by intervertebral disc herniation was
reported in the 2010 Global Burden of Disease
study to be the main reason for years lived with
disability. It causes significant personal, social,
and economic burdens. Many of those who
suffer from LBP find conventional medical
treatments to be unsatisfactory for treating their
pain, so they are increasingly resorting to
complementary and alternative medicine
(CAM) therapies. Given that the population is
aging, there is an urgent need to characterize
the combinations of complementary therapies
that yield the best outcomes and treatments,
even for prolonged periods. This observational
study aimed to evaluate the effect of ultrami-
cronized palmitoylethanolamide (umPEA) ?
CAM (daily functional rehabilitation ? decon-
tracting massage) therapies on chronic pain in
patients suffering from multiple herniated discs
in the lumbar spine.
Methods: Eligible patients received 600 mg of
umPEA twice a day in combination with a daily
functional rehabilitation session according to
the McKenzie Method of Mechanical Diagnosis
and Therapy plus a decontracting massage for
20 consecutive days, followed by 600 mg of
umPEA once a day for 40 days in addition to
standard therapy.
Results: The results showed that the average
pain intensity score, evaluated via the Numeric
Rating Scale, progressively decreased during the
study period, reaching a value that was not
clinically relevant at the end of the observation
period. Pain relief was paralleled by improve-
ments in the physical and mental components
of quality of life as evaluated with the SF-36
questionnaire as well as in disability for low
back pain as evaluated with the Oswestry Dis-
ability Questionnaire. Collectively, the results
demonstrate that umPEA in combination with
CAM therapies could be an important strategy
for combating LBP.
Conclusions: The multiple action of PEA in
combination with CAM therapies may represent
the multitarget approach needed to tackle the
as-yet unsolved problem of chronic pain resis-
tant to conventional therapies.
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Chronic low back pain (LBP) causes
significant personal, social, and economic
burdens.
Conventional medical treatments for LBP
are frequently unsatisfactory, so patients




with daily functional rehabilitation and
decontracting massage in patients affected
by multiple herniated discs in the lumbar
spine elicited progressive pain relief
paralleled by improvements in the
physical and mental components of
quality of life.
The multiple action of
palmitoylethanolamide in combination
with CAM therapies may represent the
multitarget approach needed to tackle the
as-yet unsolved problem of chronic pain
resistant to conventional therapies.
INTRODUCTION
Intervertebral disc herniation can cause back
pain and/or radiculopathy, and it accounts for a
significant proportion of the patients who have
spinal surgery around the world. Lumbar disc
herniation (LDH) is the most common cause of
low back pain (LBP) and sciatica. It occurs in
around 9% of all people worldwide, impacts
substantially on their quality of life, and repre-
sents a significant economic burden [1, 2]. In
recent years, lifestyle changes have led to a
gradual increase in the incidence of LDH, and
the mean age of onset has become younger. In
industrialized countries, LBP and sciatica are
among the leading causes of work incapacity
and disability before the age of 45 [3]. LDH has
been associated with disruption of the annulus
fibrosus, extrusion of the nucleus pulposus, and
stimulation of nerve fibers, leading to pain [2].
LBP consequent to LDH was reported to be the
main cause of years lived with disability in the
2010 Global Burden of Disease study, confirm-
ing that it is a disease that causes significant
personal, social, and economic burdens [4].
People with back pain suffer from worse physi-
cal and mental health than people without back
pain.
Recommended treatments for LDH include
surgery and conservative methods such as
transforaminal epidural steroid injection [5].
However, injections have been linked with
various serious adverse events. In addition,
although early surgical intervention is effective
at alleviating sciatica earlier than conservative
treatment, the results of surgical intervention
and conservative treatment were found to be
similar from one year onwards [6], and cases of
failed back surgery syndrome where chronic
pain persists after surgery continue to be
reported [7]. For these reasons, complementary
and alternative medicine (CAM) therapies are
gaining ever-greater recognition as a means to
treat back pain. According to the 2002 National
Health Interview Survey of the resident civilian
noninstitutionalized US population, the
majority of the respondents who used comple-
mentary and alternative medicine therapies for
back pain perceived a benefit [8]. Indeed, the
updated 2017 LBP guidelines of the American
College of Physicians recommend the use of
nonpharmacologic treatments for patients with
LBP. Guidelines also recommend the use of
exercise in combination with other nonphar-
macological therapies such as massage and
nutraceuticals with known pain-relieving
activity. One biomolecule that has been used in
the management of chronic pain is palmi-
toylethanolamide (PEA). PEA is an acylethano-
lamide that is widely distributed in different
tissues, including nervous tissues, and is syn-
thesized on demand [9]. Evidence indicates that
PEA is an important anti-inflammatory,
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analgesic, and neuroprotective mediator that
acts at several molecular targets in both the
central and peripheral nervous systems [10]. In
addition to considerable evidence from experi-
mental studies, several clinical studies pub-
lished in in recent years have confirmed that
PEA has anti-inflammatory and pain-relieving
properties in humans [10, 11]. Most clinical
trials with PEA have focused on formulations
with particles that were subjected to the so-
called fluid jet micronization process. This
yields particles with a defined size profile
(6–10 lm at most) that is completely different
from and statistically lower than that of naı¨ve
PEA (in the 100–700 lm range). This smaller
size (implying a higher surface-to-volume ratio)
along with increased potential energy of the
particles leads to better solute solubility. These
characteristics result in better diffusion and
distribution of micronized and ultramicronized
PEA compared to the naı¨ve form, and thus
superior biological efficacy [10, 12]. The prop-
erties of umPEA prompted us to investigate the
effect of umPEA ? CAM (daily functional reha-
bilitation and decontracting massage) therapies
on chronic pain in patients suffering from
multiple herniated discs in the lumbar spine.
METHODS
A prospective observational study was carried
out between March 2016 and April 2017 of
outpatients at the Complex Operating Unit—
Rehabilitation, Polyclinic University Hospital
Paolo Giaccone, Palermo (Italy). Patients
aged C 18 years old who were suffering from
chronic pain due to multiple herniated discs in
the lumbar spine were enrolled. Patient diag-
noses were checked by RMN. At the time of
enrollment (baseline), the patients were being
treated with analgesics, albeit with poor results.
However, they maintained this therapeutic
pattern, based generally on gabapentinoids or
opioids, during the study.
Standard treatment was supplemented with
600 mg of umPEA (Normast 600 mg, Epitech
Group SpA, Saccolongo, Italy) twice a day in
combination with a daily functional rehabilita-
tion session according to the McKenzie Method
of Mechanical Diagnosis and Therapy (MDT)
[13, 14] plus a decontracting massage for 20
consecutive days, and subsequently 600 mg of
umPEA once a day for 40 days. Pain intensity
was evaluated via the Numeric Rating Scale
(NRS), which consists of a 11-point grading
scale (0–10) in which a score of 0 represents the
total absence of pain and 10 corresponds to the
presence of the worst pain imaginable. Quality
of life was evaluated via the 36-Item Short Form
Health Survey questionnaire (SF-36) [15]. Dis-
ability elicited by low back pain was evaluated
by the Oswestry Disability Questionnaire (ODQ)
[16].
Statistical analysis was performed using the
generalized linear mixed model (GLMM). Vari-
ables such as gender and age were included in
the model as covariates. Data are given as the
mean ± standard error (SE) unless otherwise
stated. A p value of less than 0.05 was consid-
ered significant.
This study was performed in accordance with
the Good Clinical Practice guidelines and the
principles of the Declaration of Helsinki of 1964
and its subsequent revisions. The study was
approved by the Polyclinic University Hospital
Paolo Giaccone Ethics Committee (report
number 05/2019). Written consent for partici-
pation was obtained from each patient after
they had been fully informed of the purpose of
the study.
RESULTS
One hundred twenty patients of both genders
(37 males and 83 females) with a mean age of
56.4 ± 13.0 who were suffering from lum-
bosciatica (95) and lumbocruralgia due to mul-
tiple herniated discs in the lumbar spine (25)
were eligible for statistical analysis. The patients
reported painful symptoms suggestive of neu-
ropathic, neurogenic, or radicular pain. They
had experienced pain for about 2 years, even
though they were being treated with pregabalin
(n = 87; 75 mg, 1 capsule 2 times a day) or
oxycodone (n = 33; 5 mg, 1 capsule 2 times a
day) as their standard therapy.
With the addition of umPEA ? CAM thera-
pies to their standard therapy, their average
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pain intensity scores decreased significantly
from 6.3 ± 0.1 at baseline to 3.7 ± 0.09 and
2 ± 0.09 at 30 and 60 days, respectively
(p\ 0.001; Fig. 1).
The impact of chronic pain on quality of life
changed significantly during the course of
umPEA ? CAM therapies. The physical compo-
nent (PCS-36) increased from 30.7 ± 0.3 at
baseline to 37.1 ± 0.3 and 43.9 ± 0.4 at 30 and
60 days, respectively. The increase in PCS-36
score was already statistically significant after
30 days of treatment (p\0.0001 for 30-day vs
baseline scores), and a further increase occurred
after 60 days of treatment (p\0.0001 for
30-day vs 60-day scores). p values were evalu-
ated at net of age, which was found to influence
the response (p = 0.0009); see Table 1.
The mental component (MCS-36) was also
improved by the treatment; the MCS-36 score
was 31.4 ± 0.2 at baseline and increased to
38.1 ± 0.4 and 44.1 ± 0.4 at 30 and 60 days,
respectively (Table 1). Similarly to the PCS-36
score profile, the increase in score was already
statistically significant after 30 days of treat-
ment (p\ 0.0001 for 30-day vs baseline scores),
and a further increase occurred after 60 days of
treatment (p\0.0001 for 30-day vs 60-day
scores). The influence of the covariate age was
not relevant to the response (p = 0.06).
Disability for low back pain in patients
undergoing umPEA ? CAM therapies signifi-
cantly decreased from 44.2 ± 0.4 at baseline to
37.4 ± 0.3 and 28.7 ± 0.4 at 30 and 60 days,
respectively (p\0.001, Table 1). Statistical
analysis showed that disability improved sig-
nificantly over time (p\0.0001) and that the
effect was already significant after 30 days of
treatment (p\0.0001 for 30-day vs baseline
scores), with a further increase after 60 days of
treatment (p\0.0001 for 30-day vs 60-day
scores; Table 1). p values were evaluated at net
of age, which was found to influence the
response (p = 0.0002).
DISCUSSION
The results obtained in this observational study
confirmed that umPEA ? CAM therapies might
be beneficial to patients with LBP, given that
the average pain intensity score decreased pro-
gressively during the study period and reached a
value that was not clinically relevant at the end
of the observation period. Improvements in the
physical and mental components of quality of
life as well as disability for low back pain pro-
vide further confirmation of the beneficial effect
of umPEA ? CAM therapies.
LBP is a major public health problem, and
has been identified as a leading cause of dis-
ability worldwide. Persistent LBP is associated
with significant individual functional impair-
ment, high utilization of health care, work
absenteeism, and long-term incapacity [4].
Many people who suffer from LBP have found
conventional medical treatments to be ineffec-
tive and unreliable for treating their pain;
examples include the patients enrolled in the
present study, who were being treated with
conventional therapies that had not signifi-
cantly resolved their chronic pain. Because of
this, a large proportion of the population with
LBP have used some form of CAM therapy in
the past year, with particularly high use repor-
ted among those with limiting back pain, who
perceive a great deal of benefit from CAM [17].



















Fig. 1 Effect of adjuvant umPEA ? CAM therapies on
pain intensity scores in patients with chronic pain caused
by lumbosciatica or lumbocruralgia due to multiple
herniated discs in the lumbar spine. Data are expressed
as the mean ± SE; n = 120. Note that the pain intensity
score decreased with treatment over time: p\ 0.0001
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exercise in combination with massage as a
treatment option [18, 19]. The MDT, which
prescribes repeated exercise in a specific direc-
tion along with an educational approach, is one
of the strategies recommended by LBP guideli-
nes [20].
A recent review and meta-analysis found
moderate- to high-quality evidence that the
MDT is superior to other rehabilitation inter-
ventions at reducing pain and disability in
patients with chronic LBP; however, this
depends on the type of intervention being
compared with the MDT [21]. Moreover, a
recent study showed that patients with chronic
LBP treated using the MDT experienced only
small improvements in pain intensity at short-
term follow-up compared to the effect of a pla-
cebo [22]. These results confirm the difficulty of
treating a complex condition such as LBP with a
single therapy, and strengthen the proposal—as
already underlined in the guidelines for the
treatment of LBP—to adopt integrative care
plans instead of monodisciplinary care alone.
In line with this proposal, in the present
study, decontracting massage was performed
soon after MDT therapy, and systemic treat-
ment with umPEA was added to these physical
CAM therapies. umPEA treatment was main-
tained for 40 days after the physical CAM ther-
apies were stopped. Massage has been the focus
of several clinical trials, and an ‘‘evidence map’’
to depict the distribution of evidence available
for massage visually as well as various pain
indications for massage has recently been pub-
lished. Therapeutic massage requires no special
equipment; it can be administered almost any-
where, and there is a low likelihood of any
serious harm from massage [23]. It is beneficial
to patients with chronic LBP in terms of
improving their symptoms and function.
Decontracting massage invigorates and relaxes
the body muscles through a deep pressure
technique and energizing manual action. It is
recommended as a preparation for any sport
activity or to relieve muscle fatigue immediately
after any sport activity.
The umPEA treatment played important
roles in both the resolution of the pain and the
consequent improvement in quality of life
reported in the present study. PEA is a multiple
anti-inflammatory lipid mediator that has been
reported to have pain-relieving effects in vari-
ous chronic pain conditions with different eti-
ologies [11, 24]. It is reported that PEA may
exert both receptor-mediated and non-receptor-
mediated effects at different cellular and tissue
sites [25]. The transcription factor peroxisome
proliferator-activated receptor alpha (PPAR-a)
was identified as a possible target for the anti-
inflammatory action of PEA [26]. PEA may also
interact with other members of the PPAR family
to elicit its anti-inflammatory activity [27, 28].
PPARs are found on dorsal root ganglion sen-
sory neurons and glial cells. PEA may activate
these receptors and modulate both the percep-
tion and transmission of peripheral pain sig-
naling and spinal pain amplification mecha-
nisms, thereby exerting its influence on differ-
ent types and phases of pain [29]. PEA potenti-
ates the action of anandamide at cannabinoid
Table 1 Effect of adjuvant umPEA ? CAM therapies on quality of life and disability for low back pain in patients with
chronic pain caused by lumbosciatica or lumbocruralgia due to multiple herniated discs in the lumbar spine
Time (days) p*
0 30 60
PCS-F36 30.7 ± 0.3 37.1 ± 0.3 43.9 ± 0.4 \ 0.0001
MCS-F36 31.4 ± 0.2 38.1 ± 0.4 44.1 ± 0.4 \ 0.0001
ODQ 44.2 ± 0.4 37.4 ± 0.3 28.7 ± 0.3 \ 0.0001
Data (scores) are expressed as the mean ± SE; n = 120 at each time point
PCS-F36 physical health, MCS-F36 mental health, ODQ Oswestry Disability Questionnaire
*p is for the average scores over the observation period
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(CB) receptors in a CB2 receptor antagonist-
sensitive fashion (while having no appreciable
affinity for either CB1 or CB2 receptors) and the
anandamide-induced desensitization of tran-
sient receptor potential cation channel sub-
family V member 1 (TRPV1) channels
(‘‘entourage’’ effects). The direct activation and
desensitization of TRPV1 channels are impor-
tant mechanisms in the modulation of pain
signaling [30, 31].
The principal limitation of this study is the
lack of a comparison between the three treat-
ment strategies. However, the group of patients
examined in the present study reported that
they had been in pain for about 2 years, even
though they were using classic pain relief ther-
apies. The complexity of the condition suffered
by the patients necessitated the use of a com-
bination of therapies.
CONCLUSIONS
The results of the present study suggest that
PEA, especially when combined with other
pharmacological or nonpharmacological thera-
pies, could meet the need for a multitarget
approach to tackling the as-yet unsolved prob-
lem of chronic pain resistant to conventional
therapies [32].
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